Into 2019: Meaningful Innovation In Medtech Is Reaching A 10-Year Peak
Executive Summary
Medtech continues to outperform biotech from a sustainable investment growth point of view, and meanwhile medtech CEOs are on message about advancing value- and outcomes-based models with their provider partners. It all points to medtech being in a good place for 2019, and there is no reason for M&A and industry consolidation to stop anytime soon, says Jefferies equity analyst Raj Denhoy.
You may also be interested in...
UK Government Promise For 2021: No Halting The Advance Of Healthtech Innovation Adoption
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
UK Medtechs Determined To Exploit Digital Health Opportunity Born From The Pandemic
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
UK Device Safety To Be Enhanced By Patient Safety Commissioner
Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.
Need a specific report? 1000+ reports available
Buy Reports